Skip to main content

Table 2 Number of studies per country and vaccine type

From: Vaccine preferences driving vaccine-decision making of different target groups: a systematic review of choice-based experiments

Country Number of studies (%)a Type of vaccine Number of studies (%)a
Australia 3 (7.1) Childhood (combination) vaccines 6 (14.3)
Belgium 1 (2.4) General vaccines 3 (7.1)
Canada 1 (2.4) Hepatitis B (HepB) vaccine 2 (4.8)
China 3 (7.1) Herpes zoster vaccine 1 (2.4)
Europe (not specified) 1 (2.4) Human Papilloma Virus (HPV) vaccine 9 (21.4)
France 2 (4.8) Hypothetical vaccine 5 (11.9)
Germany 3 (7.1) Influenza vaccine 8 (19.0)
Hong Kong 3 (7.1) Leptospirosis vaccine 1 (2.4)
Hungary 1 (2.4) Meningococcal (B) vaccine 3 (7.1)
Italy 1 (2.4) Pertussis vaccine 1 (2.4)
Japan 2 (4.8) Pneumococcal vaccine 1 (2.4)
Netherlands, the 9 (21.4) Rotavirus vaccine 2 (4.8)
Philippines, the 1 (2.4) Tetanus-Diphtheria-Pertussis (Tdap) vaccine 1 (2.4)
Poland 2 (4.8) Travel vaccines 1 (2.4)
South-Africa 1 (2.4) Varicella vaccine 1 (2.4)
Spain 2 (4.8)   
Sweden 1 (2.4)   
Thailand 1 (2.4)   
United Kingdom 2 (4.8)   
Unites States of America 7 (16.7)   
Vietnam 1 (2.4)   
  1. aAs four studies included more than one country and one study covered multiple vaccines, the total number of studies exceeds the total amount of included studies (and 100%)